PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

The role of PBMs, patents, and public health in drug pricing

This is Part 1 of “Behind the Counter,” an in-depth video series demystifying the complex world of patents and drug pricing. Prescription drug costs are

June 12, 2024

AstraZeneca mulls risk strategy for Ultomiris following FDA response letter – Pharmaceutical Technology

The therapy is approved for NMOSD in multiple regions, including the European Union (EU) and Japan. Image Credit: Roland Magnusson / Shutterstock. The US Food

September 6, 2023

Describing patterns of pediatric allergies across the United States using EHR

In the largest study of its kind, researchers from Children’s Hospital of Philadelphia (CHOP) used electronic health record (EHR) data from more than 200,000 pediatric

July 25, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.